Description: ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2ion Biotechnologies ApS, researches and develops preventive and therapeutic vaccine products in the Nordics and internationally. The company's lead asset is ES2B-C001, a therapeutic vaccine for breast cancer that targets the human epidermal growth factor receptor 2 receptor. It is also developing ES2B-I002, a cytomegalovirus vaccine candidate to treat infectious diseases. In addition, the company out licenses its ExpreS2 platform to research institutes and pharmaceutical companies. Further, it sells ExpreS2 test kits and reagents for research purposes or diagnostic applications. The company has collaboration agreement with University of Oxford for the development of vaccine for malaria; and Evaxion Biotech A/S for development of cytomegalovirus vaccine, as well as partnership agreement with Copenhagen University to develop vaccine for Influenza. The company operates an online store. ExpreS2ion Biotech Holding AB (publ) was incorporated in 2015 is based in Helsingborg, Sweden.
Home Page: www.expres2ionbio.com
ROennowsgatan 8C
Helsingborg,
252 25
Sweden
Phone:
45 22 22 10 19
Officers
| Name | Title |
|---|---|
| Mr. Bent U. Frandsen MSc | Chief Executive Officer |
| Mr. Keith Alexander | Chief Financial Officer |
| Dr. Max M. Sogaard | Senior Vice President of Research & Development and Technology |
| Dr. Farshad Guirakhoo Ph.D. | Chief Scientific Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6655 |
| Price-to-Sales TTM: | 0.0176 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 18 |